sank after the company reported disappointing third-quarter results and revised its sales guidance lower. Lately, the stock was dropping $3.04, or 16.7%, to $15.19.

The company reported a loss of $5 million in the quarter, compared with $4.7 million a year ago. On a per-share basis, Senomyx lost 17 cents compared with 18 cents a year ago. Analysts surveyed by Thomson First Call expected a loss of 19 cents a share. For the full year, the company lowered its revenue guidance to between $12 million and $13 million from $14 million to $16 million.

Osiris Therapeutics

(OSIR) - Get Report

shares jumped after the company announced positive clinical trial data of its experimental Crohn's disease treatment Prochymal. The stock recently gained 11.8% to $16.79.

In midstage trials of the drug, treatment with two of the stem cell-based infusions led to a statistically significant decrease in disease activity according to a measure of patient symptoms. With relatively low doses and a short treatment course, all patients evaluated in the trial saw a reduction in the severity of the disease within 28 days, the company says.

Barr Pharmaceuticals

( BRL) has acquired 92% of Croatian pharmaceuticals company Pliva through a $2.5 billion tender offer. The company also said the Federal Trade Commission has voted 5-0 to permit the acquisition, subject to "minimal divestitures" of certain overlapping product lines.

The transaction, which is expected to close by Oct. 25, will make Pliva a Barr subsidiary and create the third-largest global generic pharmaceutical company based on revenue of approximately $2.4 billion a year. Shares of Barr added 0.2% to $52.99.

Drug development technology company


(CBM) - Get Report

has agreed to sell two plants that are part of its human health division.

The Cork, Ireland, and Landen, Belgium, facilities, which produce small-molecule, active pharmaceutical ingredients, will be sold to a subsidiary of Luxembourg's International Chemical Investors II. Cambrex was down 1.5% to $21.43.


(MRK) - Get Report

was higher after it once again raised its full-year earnings prediction. Merck now says it should make $2.48 to $2.52 a share in 2006, excluding one-time charges. The forecast tops its July guidance of $2.40 to $2.48. The company started the year with an EPS estimate of $2.28 to $2.32 before items.

Shares of Merck were up 2.2% to $45.45.

Other health stocks on the move included


(ABT) - Get Report

, 1.6% higher to $48.69,


( SHPGY) up 2.4% to $54.86,


(LCI) - Get Report

, gaining 12% to $6.45,

Dade Behring

( DADE), whose shares rose 1.3% to $38.57, and

Memory Pharmaceuticals

( MEMY), up 21.1% to $1.72.

Myriad Genetics'

(MYGN) - Get Report

shares lost 2% to $27.68,

Ariad Pharmaceuticals


fell 10.8% to $4.62,



stock lost 5.7% to $4.99,


( NTY) shares were off 1.1% to $29.51, and

IDM Pharma's

( IDMI) stock was down 10% to $2.65.